Loading
IN
Impel Neuropharma Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by NELSON TIMOTHY S, was filed 22 Nov 2021.
Impel Neuropharma Inc: what insiders have been doing
Impel Neuropharma Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Impel Neuropharma Inc has had no insider filing for more than a year; the last one goes back to 9 April 2024.
Looking back to 2021, when coverage begins, insiders filed 10 purchases and 6 sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
53
Thresholds
n/a
Buy Volume
€44M
10 ops. · all time
Sell Volume
€67,756
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$10.9M
Gross profitUS$5.3M49% margin
Net income-US$91.5M-840.3% margin
Last declaration on 9 April 2024
Declarations53 total
10,000 shares0Common StockSEC:0001415889-24-010567:0
12,066 shares@ US$0.290.0% of flowCommon StockSEC:0001213900-23-097043:1
209,029 shares@ US$0.110.3% of flowCommon StockSEC:0001213900-23-097043:2
28,682 shares@ US$0.110.0% of flowCommon StockSEC:0001213900-23-097043:3
208,657 shares@ US$0.080.2% of flowCommon StockSEC:0001213900-23-097043:4
28,632 shares@ US$0.080.0% of flowCommon StockSEC:0001213900-23-097043:5
87,934 shares@ US$0.29100.0% of flowCommon StockSEC:0001213900-23-097043:0
3,627 shares@ US$3.75100.0% of flowCommon StockSEC:0001209191-23-001365:1
10,571 shares0Common StockSEC:0001209191-23-001365:0
24,606 shares@ US$1.9763.8% of flowCommon StockSEC:0001209191-22-021673:0
20,000 shares@ US$1.64100.0% of flowCommon StockSEC:0001209191-21-071087:0
10,000 shares@ US$10.7554100.0% of flowCommon StockSEC:0001209191-21-066134:0
Canonical exit: 17 Feb 2022 (T+90)
4,650 shares@ US$2.464.6% of flowCommon StockSEC:0001209191-21-057275:1
53,954 shares@ US$2.9563.4% of flowCommon StockSEC:0001209191-21-057275:2
14,780 shares@ US$1.9736.2% of flowCommon StockSEC:0001209191-21-057275:0
2,197 shares@ US$14.9111.7% of flowCommon StockSEC:0001209191-21-052595:1
Canonical exit: 16 Nov 2021 (T+90)
600 shares@ US$15.893.4% of flowCommon StockSEC:0001209191-21-052595:2
Canonical exit: 16 Nov 2021 (T+90)
17,203 shares@ US$13.8061100.0% of flowCommon StockSEC:0001209191-21-052595:0
Canonical exit: 16 Nov 2021 (T+90)
4,253 shares0Common StockSEC:0001209191-21-038665:0
118,712 shares@ US$13.508.9% of flowCommon StockSEC:0001140361-21-014994:1
1,100,000 shares@ US$15.0091.1% of flowCommon StockSEC:0001140361-21-014994:2
Canonical exit: 26 Jul 2021 (T+90)
89,145 shares@ US$13.5012.0% of flowCommon StockSEC:0001213900-21-023652:8
12,311 shares@ US$13.501.7% of flowCommon StockSEC:0001213900-21-023652:9
505,620 shares@ US$15.0075.7% of flowCommon StockSEC:0001213900-21-023652:10
Canonical exit: 26 Jul 2021 (T+90)
69,380 shares@ US$15.0010.4% of flowCommon StockSEC:0001213900-21-023652:11
Canonical exit: 26 Jul 2021 (T+90)
25 of 53 declarations
About Impel Neuropharma Inc
Impel NeuroPharma Inc. (ticker IMPL) is a U.S.-listed biopharmaceutical company that trades on NASDAQ; it later changed its corporate name to Impel Pharmaceuticals in 2022, but many market references and SEC records still reflect the former name. For francophone investors, the company sits squarely in the health-care/pharma universe, with a business model built around drug-delivery innovation rather than a broad diversified pipeline. Impel was incorporated in Delaware on July 24, 2008, and its headquarters and principal operations are in Seattle, Washington, in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017023021513/impl-20230331.htm?utm_source=openai))
The company’s core differentiation has been its proprietary Precision Olfactory Delivery (POD) platform, designed to deliver therapies through the nasal route for rapid absorption and patient convenience. Historically, Impel described itself as a late-stage or commercial-stage biopharmaceutical company focused on transformative therapies for diseases with high unmet medical needs, initially with an emphasis on central nervous system disorders. Its lead commercial product is Trudhesa™ (dihydroergotamine mesylate) Nasal Spray, approved in the U.S. for migraine treatment and central to the company’s commercialization efforts. Beyond this asset, Impel has discussed additional product candidates and broader applications for its POD technology, but the economic profile has remained highly concentrated. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017022009951/impl-20220331.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Impel operates as a niche specialty pharma company where execution matters more than scale. Its competitive edge depends on clinical differentiation, prescriber adoption, reimbursement access, and the ability to translate a delivery-platform advantage into sustainable revenues. Rather than competing head-on with large diversified pharmaceutical companies, it is better viewed against migraine, neurology, and specialty-drug peers. The strategic logic is clear: one marketed product provides near-term commercial proof, while the POD platform offers optionality for future expansion into additional indications if development and commercialization efforts succeed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017022009951/impl-20220331.htm?utm_source=openai))
Geographically, the company is primarily U.S.-centric: it is NASDAQ-listed, headquartered in Seattle, and focused on the U.S. market for commercial execution. SEC filings also note certain research and development activities in Australia, indicating that development operations have not been entirely domestic. Recent company disclosures and filings have highlighted financing activity, commercialization of Trudhesa, and balance-sheet management—typical themes for a small-cap biotech transitioning from development into commercial execution. For investors, the key variables remain product sales traction, regulatory and market-access execution, and the company’s ability to broaden its platform beyond a single core asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000119312521269949/d593533d424b4.htm?utm_source=openai))
